MOLECULAR MODULATION OF HSV VECTOR CNS INTERACTIONS
Project Number1R01NS038577-01A1
Contact PI/Project LeaderOLSCHOWKA, JOHN A
Awardee OrganizationUNIVERSITY OF ROCHESTER
Description
Abstract Text
DESCRIPTION(adapted from applicant's abstract): With development and
application of direct gene transfer systems for the potential treatment of
neurodegenerative disease, several considerations related to vector safety and
gene product expression quickly become apparent. The current proposal will
examine whether the innate andl/or cellular arms of the irnmune system are
activated following placement of a transgene within the rnouse CNS? Two
specific aims will be addressed. The first specific aim seeks to deterrnine the
immunopathology within the mouse striatum for 3 HSV-1 based vectors: 1) lHSV-lL
plasmid based amplicon generated using a replication deficient helper virus; 2)
a plasmid-based HSV-1 amplicon produced in a helper virus-free systen about. In
both cases, the vector will express lacZ as a novel reporter gene. 3) A third
plasmid based HSV-1 amplicon produced in a helper virus-free system and
expressing mouse intestinal alkaline phosphatase (iAP) will be exarnined. The
use of iAP as the reporte:r gene will allow for easy histochemical localization
of a non CNS protein similar to 1acZ but one that should not be immunogenic.
The effects of pre-immunization with HSV will also be examined. Mouse brains
will be analyzed using both molecular analysis (quantitative PGR, RT-PCR),
immunocytochernistry and enzyme assay to correlate t]he inflammatory :response
to the viral o:r transgene proteins to transgene expressior. Analyses will
examie pro-inflammatory and inhibitory cytokines about chemokines, adhesion
molecules, blood-brain barrier irtegrity and transgene expression and survival.
The second specific aim will examine the role of the innate immune response in
li aboutting transfection efficiency. The innate immnune response (consisting
of non-specific phagocytic neutrophils and monocytes/maGrophages and driven by
the alternative complement pathway) will be examined following injection of the
HSViAP amplicon. The response will be altered in several ways. First, the
selective rernoval of either neutrophils or circulating monocytes/macrophages
will be accomplished using specific antibodies to be each cell type injected
immediately before during and after infusion of the arnplicon vecto: Secondly,
we will attempt to inhibit adhesion and limit diapedesis
utrophils/monocytes/macrophages into the transfection area using specific
antibodies to the adhesion molecules P-selectin and ICAM- 1. Third, we wil1
attempt to prevent or limit induction of pro-inflammatory cytokines, chemokines
and adhesion molecules co-expressing the inhilbitory cytokine IL-10 in our HSVi
AP vector. Finally, the role of complement in the innate immune response will
be tested by injecting recombinant Crry-Ig ip an attempt to block the role of
chemoattractants and activators of irnmune cells. The effectiveness of each
manipulation will be assayed with the same methods used in Specific Aim 1.
National Institute of Neurological Disorders and Stroke
CFDA Code
854
DUNS Number
041294109
UEI
F27KDXZMF9Y8
Project Start Date
20-April-2000
Project End Date
31-March-2004
Budget Start Date
20-April-2000
Budget End Date
31-March-2001
Project Funding Information for 2000
Total Funding
$298,606
Direct Costs
$200,000
Indirect Costs
$98,606
Year
Funding IC
FY Total Cost by IC
2000
National Institute of Neurological Disorders and Stroke
$298,606
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R01NS038577-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01NS038577-01A1
Patents
No Patents information available for 1R01NS038577-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01NS038577-01A1
Clinical Studies
No Clinical Studies information available for 1R01NS038577-01A1
News and More
Related News Releases
No news release information available for 1R01NS038577-01A1
History
No Historical information available for 1R01NS038577-01A1
Similar Projects
No Similar Projects information available for 1R01NS038577-01A1